Bayer HealthCare enters technology agreement

Animal medicine giant Bayer HealthCare has entered into a worldwide agreement with Millipore Corporation, allowing it to use its ubiquitous chromatin opening element technology to manufacture its biological drugs.

Millipore announced that, following the deal, Bayer will be able to “more efficiently manufacture recombinant proteins in mammalian cells by generating higher protein yields in its upstream bioprocessing operations”.

Andrew Bulpin, PhD, vice-president of Millipore’s Upstream Bioprocessing Business Unit, said the licence showed how the company could help pharmaceutical and biotechnology firms to manufacture drugs efficiently.

The technology allows rapid generation of small-scale proteins and can help identify cell lines which are suitable for manufacturing on a larger scale.

Millipore is a major life science company, developing and providing technologies and tools for bioscience research and biopharmaceutical manufacturing.

Last month, Bayer celebrated 20 years of manufacturing the globally-successful Baytril, which it reports is used by the “vast majority” of veterinarians across the globe.